8-K: Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Studies for Endometriosis Diagnostic Test

Aditxt's subsidiary, Pearsanta, has received IRB approval to begin clinical studies for its blood-based diagnostic test for endometriosis, aiming for a potential commercial launch in the second half of 2025.

Summary

• Aditxt, Inc. announced that its subsidiary, Pearsanta, Inc., has received IRB approval to initiate clinical studies for its blood-based diagnostic test for endometriosis.
• The test is based on Pearsanta's Mitomic platform, which identifies disruptions in mitochondrial DNA that are signatures of certain stressors on cells.
• Endometriosis affects 10-20% of women of childbearing age and often takes 5-10 years to diagnose due to the need for laparoscopic surgery.
• Pearsanta's goal is to offer a non-invasive blood test that can be used early in the diagnostic pathway to help physicians make decisions about treatment.
• The company is targeting a commercial launch in the second half of 2025, contingent on successful clinical validation.
• The clinical study will involve collecting blood samples from women undergoing diagnostic laparoscopy and comparing the test results to the surgical findings.
• The Richmond, Virginia facility is a CLIAand CAP-certified laboratory with state-of-the-art equipment and a board-certified molecular pathologist as the laboratory director.
• The company plans to continue the study to collect up to a thousand samples to understand how the test results relate to different subtypes of endometriosis and clinical attributes, keeping options open for a potential FDA submission in the future.
• The infrastructure being built for the endometriosis study will be leveraged for future cancer tests, including a prostate cancer test.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with the IRB approval and the potential for a non-invasive diagnostic test for endometriosis. The management's comments reflect a strong commitment to addressing health challenges. However, the document also acknowledges the risks and uncertainties associated with clinical studies and regulatory approvals.

Positives

• IRB approval has been granted to initiate clinical studies for the endometriosis diagnostic test.
• The test is non-invasive, offering a potential alternative to surgery.
• Early detection of endometriosis can lead to better management of the condition.
• The company has a CLIAand CAP-certified laboratory in Richmond, Virginia.
• The company is leveraging existing infrastructure for future cancer tests.
• There is potential for collaboration with Evofem to accelerate the clinical study.

Negatives

• The test is not yet commercial and requires further validation and clinical studies.
• The company needs to enroll a sufficient number of patients in the clinical study to achieve its goals.
• The company is reliant on the test working as expected.

Risks

• The clinical studies may not yield positive results, preventing commercialization of the test.
• The company may not be able to enroll enough patients in the clinical study.
• Regulatory hurdles may delay or prevent the commercial launch of the test.
• The test may not be as effective as laparoscopic surgery in diagnosing endometriosis.
• The company may face competition from other companies developing diagnostic tests for endometriosis.

Future Outlook

The company anticipates a potential commercial launch of the endometriosis test in the second half of 2025, pending successful clinical validation. They also plan to continue the study to collect up to a thousand samples to understand how the test results relate to different subtypes of endometriosis and clinical attributes, keeping options open for a potential FDA submission in the future.

Management Comments

• Amro Albanna: 'Our whole mission, our whole DNA, pun intended, is to advance innovations that could potentially address some of our most pressing health challenges.'
• Amro Albanna: 'Ultimately, we measure our success by the fact whether or not we can address real life health challenges for humans, period.'
• Steve Varvel: 'Weve got a wonderful state-of-the-art laboratory here in Richmond, 25,000 square feet here, downtown in the Biotech Center of Richmond.'

Industry Context

The announcement aligns with the growing trend of early disease detection and the development of non-invasive diagnostic tools. The endometriosis diagnostic market is driven by the need for less invasive and more accurate diagnostic methods. Companies like Roche and Abbott are also involved in developing diagnostic solutions for women's health.

Comparison to Industry Standards

• The current standard for endometriosis diagnosis is laparoscopic surgery, a procedure that is invasive and can lead to delays in diagnosis.
• Other companies, such as Roche and Abbott, are developing diagnostic solutions for women's health, but Pearsanta's approach focuses on mitochondrial DNA, which may offer a unique advantage in early detection.
• The company's CLIAand CAP-certified laboratory in Richmond, Virginia, meets industry standards for diagnostic testing facilities.
• The company's goal of launching the test as an LDT (Lab-Developed Test) is a common pathway for diagnostic tests that are developed and validated in a single laboratory.

Stakeholder Impact

• Shareholders: Positive news regarding the progress of Pearsanta's diagnostic test.
• Employees: Opportunity to contribute to the development of a novel diagnostic test.
• Customers (Women): Potential for a non-invasive diagnostic test for endometriosis.
• Suppliers: Potential for increased demand for laboratory supplies and services.
• Creditors: No immediate impact.

Next Steps

• Complete the clinical validation of the endometriosis diagnostic test.
• Enroll patients in the clinical study.
• Analyze the data from the clinical study.
• Prepare for the commercial launch of the test in the second half of 2025.
• Continue the study to collect up to a thousand samples.
• Explore potential FDA submission in the future.
• Leverage the infrastructure built for the endometriosis study for future cancer tests, including a prostate cancer test.

Key Dates

Keywords

endometriosis, diagnostic test, Pearsanta, Aditxt, clinical studies, mitochondrial DNA, early detection, womens health, IRB approval, blood test